Clik here to view.
ABEC推出面向生物制药行业的大规模单次使用微生物发酵解决方案
宾夕法尼亚州伯利恒 (美国商业资讯) — 全球领先的生物制药制造一体化解决方案及服务提供商ABEC今天发布了大规模单次使用微生物发酵能力。ABEC的CSR技术展现了一流性能，工作容量最高达1,000升。...
View ArticleClik here to view.
Octapharma集团发布2017年年报，公司实现了17.2亿欧元的营收，3.49亿欧元的运营收入
瑞士拉亨 (美国商业资讯)–过去六年间，Octapharma集团达到15%的惊人年复合增长率，2017年年报再次显示破纪录的财务结果，销售额达17.2亿欧元，与2016年相比增加1.2亿欧元（7.5%）（以固定货币为基础，增速为9.4%）。...
View ArticleClik here to view.
オクタファルマ・グループが2017年業績を発表：17億2000万ユーロの売上高と3億4900万ユーロの営業利益を計上
スイス・ラーヘン （ビジネスワイヤ） — オクタファルマ・グループは過去6年間にわたり、15%という見事な年平均成長率を達成し、さらに2017年も記録を更新して売上高17億2000万ユーロの業績を計上しました。この売上高は2016年より1億2000万ユーロの増加（7.5%増）（恒常通貨ベースの成長率は9.4%）となります。...
View ArticleClik here to view.
Certara社がVirtual Twin™テクノロジーのPoCを発表
ニュージャージー州プリンストン （ビジネスワイヤ） — モデルを活かした医薬品開発とレギュラトリー・サイエンスの分野で世界をリードするCertara®社は、Virtual Twin™テクノロジーのProof of Concept（PoC）を示す2本の論文を発表したことを本日公表いたしました。 「当社のVirtual...
View ArticleClik here to view.
Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in...
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with epidermal growth factor receptor...
View ArticleClik here to view.
Fifty-Two Week Safety Study on Symproic® (naldemedine) for Opioid-induced...
OSAKA, Japan & FLORHAM PARK, N.J. & STAMFORD, Conn. Shionogi Inc. and Purdue Pharma L.P. today announced the publication of a study known as COMPOSE-3. The study is the first to investigate...
View ArticleClik here to view.
Synergy Biomedical Announces Regulatory Clearance and Launch of BIOSPHERE...
COLLEGEVILLE, Pa. Synergy Biomedical, LLC, a developer of orthobiologic and biomaterial products, announced that it has received Therapeutic Goods Administration (TGA) clearance in Australia for its...
View ArticleClik here to view.
Second Sight Medical Products, Inc. to Present at the B. Riley & Co. China...
SYLMAR, Calif. Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to...
View ArticleClik here to view.
AmpliPhi Biosciences Announces Presentation of Preclinical Data Demonstrating...
SAN DIEGO AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections,...
View ArticleClik here to view.
Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Investing &...
CAMBRIDGE, Mass. Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough,...
View ArticleClik here to view.
Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel...
TOKYO & LONDON Sosei Group (“Sosei” or the “Company”; TOKYO Mothers Index: 4565), the world leader in GPCR medicine design and development, announced that it has regained worldwide rights from...
View ArticleClik here to view.
サンバイオと日立化成：再生医療等製品「SB623」の製造に関する業務提携に合意
東京 （ビジネスワイヤ） – サンバイオグループ（本社：東京都中央区、社長：森 敬太、以下「サンバイオ」）と日立化成株式会社（本社：東京都千代田区、執行役社長：丸山 寿、以下「日立化成」）は、この度サンバイオと、日立化成の子会社で再生医療等製品*1の受託製造事業を行うHitachi Chemical Advanced Therapeutics Solutions,...
View ArticleClik here to view.
SanBio Reaches Agreement on Manufacture of Regenerative Medicine Product...
TOKYO SanBio Group and Hitachi Chemical Co., Ltd. (Hitachi Chemical) jointly announced today that, through an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS; formerly...
View ArticleClik here to view.
PAREXEL and CHA Medical Group Partner to Enhance Early Phase Clinical...
BOSTON PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today announced an alliance with CHA Medical Group (CHA) to enhance early phase clinical...
View ArticleClik here to view.
World’s First Portable Fingerprint Drug Test Now Available in Australia and...
LONDON & MELBOURNE The world’s first portable fingerprint-based drug test – which works by analysing sweat from a fingerprint to determine if someone has recently used cocaine, opiates,...
View ArticleClik here to view.
Alexion Announces Positive Top-Line Results Showing Successful Phase 3...
NEW HAVEN, Conn. Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the pivotal Phase 3 study of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor,...
View ArticleClik here to view.
Cellvizio® Obtains Positive Assessment from the Korean National...
PARIS Regulatory News: Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary probe-based confocal laser endomicroscopy (pCLE) platform, today announced...
View ArticleClik here to view.
Foundation Medicine Advances Patient Access to Precision Medicine; Pursues...
CAMBRIDGE, Mass. Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519), one of Japan’s leading research-based pharmaceutical companies and a...
View ArticleClik here to view.
牛津纳米孔科技有限公司宣布获得来自全球知名投资机构1亿英镑（约1.39亿美元）的投资
英国 , 牛津 牛津纳米孔科技有限公司（Oxford Nanopore Technologies...
View ArticleClik here to view.
Oxford Nanopore Announces £100 Million ($140M) Fundraising from Global Investors
OXFORD, England Oxford Nanopore Technologies Ltd, the company behind the only portable real-time DNA/RNA sequencer, MinION, has raised £100M ($140M) in new investment. Funds were raised from global...
View Article